Treatment of acute neonatal bacterial conjunctivitis: a comparison of fucidic acid to chloramphenicol eye drops

Normann, Erik Kreyberg; Bakken, Odd; Peltola, J.; Andréasson, Bengt; Buhl, Susanne; Sigg, P.; Nielsen, Klaus

doi:10.1034/j.1600-0420.2002.800212.x

Cited by 27 publications

(15 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Correspondingly, several studies have shown a slight, but statistically significant, improvement of treatment compliance by using Fucithalmic ® rather than chloramphenicol eye drops in acute bacterial conjunctivitis (Carr 1998; Jackson et al. 2002; Normann et al. 2002).…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Acute bacterial conjunctivitis

Høvding

2008

Acta Ophthalmologica

186

174

View full text Add to dashboard Cite

ABSTRACT.Acute bacterial conjunctivitis is the eye disease most commonly seen by general practitioners, and is estimated to represent approximately 1% of all consultations in primary care. This article gives a review of the epidemiology, aetiology, clinical picture, complications, differential diagnoses, in vitro examinations and therapy of acute bacterial conjunctivitis. Until now, topical antibacterial therapy has generally been preferred by both physicians and patients because this will usually shorten the course of the disease slightly and allow the early readmittance of children to their kindergarten or school. Recently, several reports from primary care have confirmed the well-known clinical experience that the disorder has an excellent prognosis with a high frequency of spontaneous remission. In accordance, an expectant attitude or delayed prescription policy are now frequently strongly recommended. However, these reports also emphasize the difficulty in making a correct clinical distinction between bacterial and viral conjunctivitis. The effect of a general non-prescription attitude on transmission rates of pathogens also remains to be clarified. This must be born in mind when deciding how these patients should be handled. The socioeconomic and medical pros and cons of different treatment policies are discussed, and a highly personal view on the optimal handling strategy for these patients is also presented.

show abstract

Section: Treatmentmentioning

confidence: 99%

“…Conjunctivitis caused by S. aureus is most frequently seen in neonates and in older children, as well as in adults and the elderly (Dannevig et al. 1992; Normann et al. 2002; Orden Martinez et al.…”

Section: Aetiologymentioning

confidence: 99%

Acute bacterial conjunctivitis

Høvding

2008

Acta Ophthalmologica

186

174

View full text Add to dashboard Cite

show abstract

“…These are likely to include early morning ‘glued’ eyes that result from mucopurulent discharge (Adenis et al. , 1989; Carr, 1998; Normann et al. , 2002; Rietveld et al.…”

Section: Overview Of Bacterial Infections and Their Presentationmentioning

confidence: 99%

Fusidic acid viscous eyedrops – an evaluation of pharmacodynamics, pharmacokinetics and clinical use for UK optometrists

Doughty¹,

Dutton²

2006

Ophthalmic Physiologic Optic

View full text Add to dashboard Cite

Recent changes in UK law have allowed UK-based optometrists to sell and supply fusidic acid viscous eyedrops, providing it is in the course of their professional activity and in an emergency. Alternatively, the optometrist may access fusidic acid viscous eyedrops, for a named patient, using a written order supplied to a pharmacy. This review provides details of the legal background to these changes, examines the common causes of a bacterial conjunctivitis, examines the mechanism of action of this narrow spectrum antibiotic as a bacteriostatic agent, reviews the susceptibility of common ocular isolates of bacteria to the drug and presents details of the expected pharmacokinetics of the viscous eyedrops. From this perspective, a systematic review is provided of the clinical studies which have investigated the use of fusidic acid viscous eyedrops and their outcome. The indicated use is generally for the treatment of bacterial conjunctivitis and/or blepharoconjunctivitis, especially that caused by Staphylococcus, but not Streptococcus or Haemophilus sp. (more likely associated with concurrent nasopharyngeal infections). The usual regimen for use is twice daily for 5-10 days, depending on severity, and can initially be used more intensively (four times per day). It may also be used for the management of corneal and conjunctival abrasions and foreign body injuries, or some cases of chronic blepharitis.

show abstract

“…Many investigations have shown that fusidic acid highly competitive in its efficacy with such antibiotics as tobramycin, lomefloxacin, rifampicin, and chloramphenicol [5][6][7][8][9][10]13]. Fusidic acid drug is known to be used in dacryocystitis of newborns [4,11]. In this pathology, the drug of choice is medications with a wide spectrum of antibacterial action [1].…”

Section: Introductionmentioning

confidence: 99%

“…E.K. Norman et al (2002) used Fucithalmic, a fusidic acid drug in the treatment of acute neonatal conjunctivitis [11]. R. P. Rietveld et al (2005) used 1% fusidic acid gel in the treatment of acute infectious conjunctivitis [12].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of using antibacterial fusidic acid drops in patients with red eye

Drozhzhyna¹,

Sereda²,

Gaydamaka³

et al. 2017

Oftalmol Zh

View full text Add to dashboard Cite

Introduction. A red eye includes various etiology diseases of the ocular surface (eyelids, conjunctiva, and cornea) as well as of the vascular tract and lacrimal apparatus, the main feature of which is hyperemia of the conjunctiva of the eye. The purpose of the present study was to study the efficacy of antibacterial fusidic acid drug in patients with the red eye. Material and Methods. We observed 60 patients (120 eyes) with the red eye. In case that conjunctival flora was sensitive to Futaron, the patients were prescribed the drug instillations 4 times a day for 7 days followed by repeated microbiological control. Efficacy of Futaron was determined due to terms and occurrence of pathogen eradication according to data of microbiological test of the conjunctival discharge. Results. When performing the microbiology test of the conjunctival discharge, Staphylococcus epidermidis was noted in 31 patients (51.6%). Of them, after Futaron instillations, reseeding was pure in 23 patients, and staphylococcus growth continued in 8 patients (25.6%). In all twelve patients (20%) with Moraxella determined, agent eradication was achieved against the background of Futaron instillations. Streptococcus haemolyticus was detected in the culture from the conjunctiva in seven patients (11.7%). Herewith, reseeding was pure in four patients (57.2%) and staphylococcus persistence was noted in three of them (42.8%). Futaron instillations for 7 days facilitated pathogenic flora eradication in four patients (6.7%) with Escherichia coli defined and in three patients (5%) with Staphylococcus aureus. Conclusions. Futaron eye drops is an effective and safe drug for treatment of red eye patients and they are most effective when Staphylococcus epidermidis and Moraxella are defined in the culture from the conjunctiva.

show abstract

Treatment of acute neonatal bacterial conjunctivitis: a comparison of fucidic acid to chloramphenicol eye drops

Cited by 27 publications

References 12 publications

Acute bacterial conjunctivitis

Acute bacterial conjunctivitis

Fusidic acid viscous eyedrops – an evaluation of pharmacodynamics, pharmacokinetics and clinical use for UK optometrists

Efficacy of using antibacterial fusidic acid drops in patients with red eye

Contact Info

Product

Resources

About